Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar pchop123 (79.46) Submitted: 11/16/2012 1:47:11 PM : Underperform Start Price: $2.41 DVAX Score: -11.75

This recent downside is way overdone and you should take advantage of it !!!

Member Avatar TSIF (99.96) Submitted: 11/16/2012 4:27:55 PM
Recs: 0

Doesn't really sound like a downthumb pitch?? :)

Featured Broker Partners


Advertisement